Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.38 |
| ▸ | CTSH | P09668 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328858 | 0.81 | SLC1A3 (0.40) | CTSKCTSLCTSBLTA4HSLC1A3 | |
| SCHEMBL28191857 | 0.81 | SLC1A3 (0.40) | CTSKCTSLCTSBLTA4HSLC1A3 | |
| SCHEMBL7492172 | 0.78 | CTSK (0.39) | CTSKCTSLCTSBLTA4HSLC1A3 | |
| SCHEMBL26940460 | 0.78 | SLC1A3 (0.41) | CTSKLTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7495648 | 0.78 | CTSK (0.39) | CTSKCTSLCTSBLTA4HSLC1A3 | |
| SCHEMBL16563050 | 0.76 | CTSK (0.41) | CTSKCTSLCTSBLTA4HSLC1A3 | |
| SCHEMBL7953083 | 0.76 | CTSK (0.41) | CTSKCTSLCTSBLTA4HSLC1A3 | |
| SCHEMBL17939425 | 0.76 | CTSK (0.41) | CTSKCTSLCTSBLTA4HSLC1A3 | |
| SCHEMBL24328859 | 0.76 | SELE (0.39) | CTSKLTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24308310 | 0.75 | CTSK (0.44) | CTSKCTSLCTSBLTA4HCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | CTSK 2134/4885CTSL 2171/4885CTSB 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.